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Abstract  
 
Little is known about how interactions between diet, immune recognition, and intestinal 
stem cells (ISCs) impact the early steps of intestinal tumorigenesis. Here, we show that 
a high fat diet (HFD) reduces the expression of the major histocompatibility complex II 
(MHC-II) genes in ISCs. This decline in ISC MHC-II expression in a HFD correlates with 
an altered intestinal microbiome composition and is recapitulated in antibiotic treated 
and germ-free mice on a control diet. Mechanistically, pattern recognition receptor and 
IFNg signaling regulate MHC-II expression in ISCs.  Although MHC-II expression on 
ISCs is dispensable for stem cell function in organoid cultures in vitro, upon loss of the 
tumor suppressor gene Apc in a HFD, MHC-II-  ISCs harbor greater in vivo tumor-
initiating capacity than their MHC-II+ counterparts, thus implicating a role for epithelial 
MHC-II in suppressing tumorigenesis. Finally, ISC-specific genetic ablation of MHC-II in 
engineered Apc-mediated intestinal tumor models increases tumor burden in a cell 
autonomous manner. These findings highlight how a HFD alters the immune recognition 
properties of ISCs through the regulation of MHC-II expression in a manner that could 
contribute to intestinal tumorigenesis. 
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Introduction  
 
 Diet is a major lifestyle factor that influences health and disease states, including 
cancer (Beyaz and Yilmaz, 2016; Zitvogel et al., 2017). Significant epidemiologic and 
preclinical studies link obesity to intestinal cancer incidence. However, how the 
adaptation of the intestinal epithelium to pro-obesity diets alters the cancer risk remains 
elusive (Basen-Engquist and Chang, 2011; Calle et al., 2003; Gallagher and LeRoith, 
2015). The intestinal epithelium is maintained by Lgr5+ intestinal stem cells (ISCs) that 
reside at the crypt base and give rise to the diverse, specialized cell types of the 
intestinal lining (Barker et al., 2007). These rapidly renewing ISCs coordinate intestinal 
adaptation in response to environmental inputs such as diet by balancing stem cell self-
renewal with differentiation divisions (Beyaz et al., 2016; Wang et al., 2018; Yang et al., 
2008; Yilmaz et al., 2012). ISCs are also the cells-of-origin for many early intestinal 
tumors and lie at the interface of dietary nutrients, commensal microbes and immune 
cells. Thus, understanding how diet induces changes in ISCs and their surrounding 
components may shed light on the early steps involved in initiation of intestinal cancers 
(Barker et al., 2009; Belkaid and Hand, 2014; Clevers, 2013; Hooper et al., 2012; 
Thaiss et al., 2016).  
 
We recently demonstrated that a pro-obesity high fat diet (HFD) enhances 
intestinal tumorigenicity in part by boosting intestinal stem cell (ISC) and progenitor cell 
function and increasing the ability of these cells to undergo oncogenic transformation 
upon loss of the tumor suppressor gene Apc (Beyaz et al., 2016). Because interactions 
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between cancer cells and the immune system influence tumor initiation and 
progression, it is important to understand the crosstalk between tumor-initiating ISCs 
and immune cells. Although cancers develop several strategies to evade the immune 
system (Grasso et al., 2018; Liu et al., 2017), little is known about how diet-induced 
obesity impacts the interaction of ISCs with the immune system at the start of tumor 
formation.  
 
Results 
HFD dampens MHC-II expression in ISCs 
To explore how a high fat diet (HFD) perturbs immunomodulatory gene 
expression in ISCs, we examined our previous mRNA-sequencing (RNA-seq) dataset of 
Lgr5+ ISCs isolated from control and HFD-fed mice (Beyaz et al., 2016). We found that 
ISCs derived from HFD-fed mice significantly downregulate immunomodulatory genes 
that are involved in the MHC-II pathway (H2-Aa, H2-Ab1, Ciita), anti-microbial 
response/inflammation (Reg3g, Nfkb2) and costimulation (Icosl, Sectm1a, Sectm1b) 
(Choi et al., 2011; Dong et al., 2001; Howie et al., 2013; Mukherjee and Hooper, 2015; 
Tomas et al., 2016) (Fig. 1A, S1A). Given the recently reported heterogeneity within 
ISCs(Barriga et al., 2017; Biton et al., 2018b), we next performed single-cell RNA-Seq 
(scRNA-Seq) of ISCs derived from control or HFD mice. Consistent with the bulk RNA-
seq profiles, H2-Ab1, a key component of MHC-II complex, was among the top 5 
differentially expressed genes with > 3-fold higher expression in control compared to 
HFD ISCs (Fig. 1B, S1B, C) (see methods, MAST test, p < 1e-10)). To determine the 
extent of MHC-II downregulation in response to HFD in our scRNA-seq data, we ranked 
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individual ISCs based on their expression pattern of MHC-II pathway genes (MHC-II 
score, Table 1) and found that HFD ISCs had consistently lower MHC-II score 
compared to control ISCs (Fig. 1C). We then selected the upper and lower quartiles and 
performed differential expression analysis between MHC-II low and MHC-II high HFD 
ISCs. As expected, MHC-II pathway genes (H2-Ab1, Cd74, H2-Aa, H2-DMa) were 
amongst the top upregulated genes in MHC-II high cells. The genes that were 
upregulated in MHC-II low cells include the fatty acid-binding protein Fabp2, 
chaperones Dnajc2 and Hspd1 (Fig. 1D). 
 
Although MHC-II expression and function is generally considered to be restricted 
to professional antigen presenting cells, several studies have demonstrated that 
intestinal epithelial cells (IECs) express high levels of MHC-II and are able to capture, 
process and present antigens to CD4+ T cells, including recent work from our group on 
ISCs (Biton et al., 2018b; Cerf-Bensussan et al., 1984; Dahan et al., 2007; Hershberg et 
al., 1997; Telega et al., 2000; Thelemann et al., 2014; Westendorf et al., 2009) (Fig. 
S1F). We validated the reduction of MHC II expression on IECs and  ISCs under a HFD 
in several ways. In situ hybridization for H2-Ab1 showed that MHC-II is expressed in the 
epithelium of control mice epithelium, but was dampened in HFD mice throughout the 
epithelium, including in the intestinal crypt where ISCs reside (Fig. 1E). Moreover, by 
flow cytometry, both Epcam+ IECs (Fig. 1F, G) and Lgr5+ ISCs (Fig. 1I, J) expressed 
high levels of MHC-II protein on their cell surface at steady state, and this expression 
was significantly downregulated in response to a HFD. Finally, we confirmed that sorted 
Epcam+ IECs (Fig. 1H) and Lgr5+ ISCs (Fig. 1K) from HFD-fed mice significantly 
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downregulated MHC-II expression by qPCR. We then partitioned ISCs into two 
subpopulations based on their MHC-II expression pattern: MHC-II+ and MHC-II- and 
assessed their frequencies in control or HFD-fed mice. While in control mice most ISCs 
were MHC-II+, a HFD led to a significant reduction in the frequency of MHC-II+ ISCs 
and to a concomitant increase in the frequency of MHC-II- ISCs (Fig. 1L, M). We sorted 
these ISC subpopulations to confirm MHC-II expression levels. Consistent with our 
scRNA-seq analysis, the expression levels of H2-Ab1 mRNA was differentially 
expressed in these subpopulations both in control and HFD-fed mice, with a significant 
reduction in response to HFD (Fig. S1D). Altogether, these results indicate HFD leads 
to suppression of MHC-II expression in the intestinal epithelial cells including ISCs. 
 
PPAR- δ activation or obesity does not affect MHC-II expression in ISCs 
A HFD perturbs multiple epithelial-intrinsic and -extrinsic pathways that may 
influence the regulation of MHC-II expression in ISCs(Fu et al., 2019; Schulz et al., 
2014). Because our prior findings demonstrated that a PPAR program mediates many 
of the effects of a HFD in ISCs (Beyaz et al., 2016; Beyaz and Yilmaz, 2016), we next 
assessed the activation status of a PPAR-δ program in ISCs based on their MHC-II 
expression pattern in response to a HFD. We found no difference in the expression 
levels of signature the PPAR-δ target genes Hmgcs2 and Jag1, or the stem cell marker 
Lgr5 in MHC-II+ and MHC-II- ISCs in both diet groups (Fig. S1E). Interestingly, agonist-
induced PPAR-d activation also did not reduce MHC-II expression in ISCs, indicating 
that HFD-induced MHC-II downregulation is independent of PPAR-δ  activity in ISCs 
(Fig. S1I, J). To determine whether MHC-II expression in ISCs is reduced in an 
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independent model of obesity, we examined leptin receptor deficient (db/db) mice, an 
obesity model that develops on a control diet(Beyaz et al., 2016) (Fig. S1H). Lgr5+ ISCs 
isolated from both lean control (db/+) and obese (db/db) mice expressed high levels of 
MHC-II, indicating that diet-induced alterations rather than obesity per se inhibits MHC-II 
expression in ISCs (Fig. S1K, L). 
 
MHC-II expression in ISCs does not influence organoid-forming capacity   
  We next assessed whether HFD-mediated downregulation of MHC-II affects 
stemness. First, we assayed the functional potential of MHC-II+ and MHC-II- ISCs, 
using an in vitro approach based on the ability of isolated ISCs to form organoid bodies 
in 3-D culture (Beyaz et al., 2016; Sato et al., 2009a). MHC-II expression levels in 
control and HFD ISCs did not affect in vitro organoid formation (Fig. S1F). To further 
ascertain whether MHC-II expression regulates ISC function, we generated mice with 
intestinal epithelium-specific MHC-II deletion (vil-iKO; see Methods). Intestinal specific 
loss of MHC-II did not affect the weight and length of the small intestine or impact crypt 
depth and villi height (Fig. S2A-G). Furthermore, the proliferation or organoid-forming 
capacity of ISCs was unaltered upon loss of MHC-II in the intestinal epithelium (Fig. 
S3A-F). To assess how MHC-II regulates ISC function specifically, we ablated MHC-II in 
Lgr5+ ISCs (Lgr5-iKO; see Methods) and found that loss of MHC-II in ISCs did not affect 
the capacity of ISCs to initiate organoids (Fig. S3G-H). To determine how MHC-II 
influences Lgr5+ ISC function in vivo, we performed LacZ lineage tracing analysis and 
did not detect a significant difference in LacZ+ cells between WT and Lgr5-iKO mice. 
While these data show that the in vitro organoid-forming capacity of ISCs is 
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independent of MHC-II expression and that MHC-II loss does not grossly alter intestinal 
homeostasis and ISC output (i.e LacZ+ progeny) at steady state, as we previously 
reported(Biton et al., 2018a) MHC-II may influence ISC differentiation through engaging 
with T helper cell cytokines in the context of inflammation (Fig. S2I). 
 
MHC-II expression on ISCs depends on the intestinal microbiome 
 The intestinal microbiome plays a significant role in regulating intestinal immunity 
(Belkaid and Hand, 2014; David et al., 2014; Hooper et al., 2012; Round and 
Mazmanian, 2009; Thaiss et al., 2016). Since dietary perturbations are among the major 
external factors shaping the intestinal microbiome, we asked whether HFD-induced 
alterations in the microbiome influence MHC-II expression in ISCs and the intestinal 
epithelium. Consistent with previous findings, HFD-induced obesity led to microbial 
dysbiosis with reduced bacterial diversity (Fig. S4A, B) (Ley et al., 2005; Schulz et al., 
2014). To determine whether the microbiome is involved in regulation of epithelial MHC-
II levels, we treated mice with broad-spectrum antibiotics, which ablated bacterial 
diversity and massiviely altered community composition (Fig. S4A, B). Notably, 
antibiotic treatment was accompanied by decreased MHC-II expression in ISCs and the 
intestinal epithelium (Fig. 2A, B), comparable to that observed in HFD. To further 
corroborate the role of the intestinal microbiome on MHC-II expression on ISCs, we 
generated germ-free Lgr5-GFP-IRES-CreERT2 mice. ISCs from germ-free mice 
exhibited reduced MHC-II expression both at RNA and protein levels compared to 
specific pathogen-free control mice (Fig. 2C-F, S4C, D). 
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To gain insight into the spectrum of members of the bacterial microbiome 
capable of inducing ISC MHC-II expression, we performed comparative 16S rDNA 
sequencing in HFD-treated mice and controls. Among the bacterial genera most 
strongly ablated under HFD conditions was Helicobacter (Fig. 2G). To determine 
whether Helicobacter colonization in mice correlates with the epithelial MHC-II 
expression in the intestine, we surveyed our mouse facility for presence or absence of 
Helicobacter species. We determined two separate rooms with mice either naturally 
colonized with Helicobacter species (H+, dirty room) or without detectable Helicobacter 
species (H-, clean room) (Fig. 2H). Notably, MHC-II expression was significantly higher 
in the intestinal epithelium of mice that are housed in dirty room compared to the mice 
housed in clean room (Fig. 2I). Comparison of microbial composition between dirty mice 
and clean mice revealed additional bacteria that are more abundant in dirty mice and 
associate with high epithelial MHC-II expression (Fig. 2J, S4E). These include 
Odoribacter sp. and Helicobacter sp., which were both ablated in response HFD (Fig. 
2G, S4E). To determine whether colonization of clean mice with the microbial flora of 
the dirty mice enhances expression of epithelial MHC-II, we co-housed clean mice with 
dirty mice in the dirty room (Fig. S4G). While clean and dirty mice have distinct microbial 
composition at baseline as determined by principal component analysis (PCA), after co-
housing the microbial profile of clean mice resembles the dirty mice (Fig. S4G). 
Importantly, co-housing with dirty mice led to a significant increase in Helicobacter sp. 
abundance in the co-housed clean mice with a concomitant upregulation of epithelial 
MHC-II compared to mice always remained in the clean room (Fig. 2K-N). These results 
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indicate that MHC-II expression in ISCs is regulated by intestinal commensal bacteria 
including Helicobacter sp., which is altered in response to a HFD.  
 
Pattern recognition receptor (PRR) and IFN γ signaling regulate MHC-II expression 
in ISCs 
Microbiome-induced activation of pattern recognition receptor (PRR) signaling or 
proinflammatory cytokines induce MHC-II expression in antigen presenting cells and 
regulate intestinal homeostasis (Abreu, 2010; Rakoff-Nahoum et al., 2004; van den 
Elsen, 2011). We surveyed PRR expression patterns in ISCs in control and HFD 
conditions. Consistent with previous reports (Brown et al., 2014; Caruso et al., 2014; 
Neal et al., 2012; Price et al., 2018), ISCs expressed several Toll-like receptors (Tlr1, 
Tlr2, Tlr3 and Tlr4), as well as Nod-like receptors (Nod1, Nod2) (Fig. 3A). Among these 
PRRs, Tlr2 and Nod2 were downregulated in response to a HFD (Fig. 3A). To test 
whether activation of TLR2 and NOD2 pathways is sufficient to increase MHC-II 
expression in ISCs, we treated mice with a dual TLR2/NOD2 agonist (CL429) (Pavot et 
al., 2014). Indeed, CL429 treatment led to significant upregulation of MHC-II in both 
control and HFD ISCs, suggesting that signaling through TLR2 and NOD2 can induce 
MHC-II expression (Fig. 3B, S5A, B). Of note, CL429 treatment did not fully restore 
MHC-II levels of HFD-treated mice to control mice, which indicates that additional 
signaling pathways may be perturbed (Fig. 3B, S5A, B). To determine the necessity of 
PRR signaling through the adaptor protein Myd88 in regulating MHC-II expression, we 
utilized intestine-specific Myd88-deficient mice (Myd88 iKO) and found significant 
downregulation of intestinal MHC-II compared to wild-type controls (Fig. S5C, D).  
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The intestinal microbiome also influences the activity of proinflammatory cytokine 
signaling, such as the proinflammatory cytokine interferon-gamma (IFN γ) and 
downstream JAK1/2 signaling pathways (van den Elsen, 2011). IFN γ is a potent 
inducer of MHC-II expression in antigen presenting cells and other cell types including 
intestinal epithelial cells (Collins et al., 1984; Thelemann et al., 2014; Wong et al., 
1984). We examined the responsiveness to IFNγ of MHC-II+ and MHC-II- HFD ISCs, 
which express similar levels of the IFNγ receptors Ifngr1 and Ifngr2 (Fig S1E). IFNγ 
treatment led to upregulation of MHC-II in both MHC-II+ and MHC-II- ISCs (Fig. S5E), 
suggesting that although HFD ISCs express lower levels of MHC-II, they are still 
responsive to IFNγ stimulation (Choi et al., 2011; Thelemann et al., 2014). To determine 
whether HFD leads to suppression of epithelial MHC-II expression through dampening 
IFN γ signaling, we assessed the expression levels of IFN γ-induced genes in control 
and HFD ISCs. We found ISCs significantly downregulate IFN γ-induced genes, 
including MHC-II pathway genes (H2-Ab1, H2-Aa, Ciita, Cd74, H2-DMa) and upstream 
pathway genes that regulate MHC-II expression (Stat1, Stat3, Nfkb2, Jak3) in response 
to HFD (Fig. 3C, D, S5F, G). Of note, the levels of IFNγ were significantly reduced in the 
intestines of HFD mice (Fig. 3E). Notably, administration of a potent JAK1/2 & 
TBK1/IKKε inhibitor (CYT378) that inhibits both STAT and NFκB signaling to mice 
significantly downregulated MHC-II expression in ISCs compared to vehicle-treated 
controls (Fig. 3E-H, S5H, I) (Tyner et al., 2010). We next asked whether IFN γ-induced 
epithelial MHC-II expression is inhibited by CYT378 in in vitro organoid assays. 
Strikingly, CYT378 blunted the induction of MHC-II expression in response to IFN γ (Fig. 
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3J). We assessed the necessity of IFN γ-signaling in regulating MHC-II expression by 
utilizing IFNGR knockout mice and found dampened epithelial MHC-II expression in 
IFNGR knockout mice compared to wild-type controls (Figure 3K). HFD-mediated 
reduction in IFN γ-inducible and MHC-II pathway gene expression in ISCs posits the 
possibility that intestinal immune cells may be depleted in the intestinal epithelium. 
Indeed, we found significant reduction in CD45+ immune cells infiltration to the crypt 
epithelium, including CD3+, CD8+ and CD4+ T cells (Figure S6A-H). Altogether, these 
results suggest that PRR and IFN γ signaling drive MHC-II expression in the intestinal 
epithelial cells including ISCs and that HFD attenuates MHC-II expression in ISCs by 
perturbing these pathways. Our data is consistent with previous studies that 
demonstrated reduced inflammation and immune infiltration in the intestinal crypt in 
response to a HFD (Beyaz et al., 2016; Johnson et al., 2015; Schulz et al., 2014).  
 
Dampening MHC-II expression in premalignant ISCs increases intestinal 
tumorigenesis 
Recognition of antigens by T cells through antigen presentation pathways is a 
major mechanism for triggering anti-tumor immunity (Vanneman and Dranoff, 2012). 
Dampening the expression of genes involved in antigen presentation to evade anti-
tumor immune responses is a hallmark of many cancers and correlates with poor 
prognosis (Lovig et al., 2002; Rimsza et al., 2004; Tarafdar et al., 2017). We found that 
adenomas arising in HFD-fed mice upon loss of Apc expressed less MHC-II than 
controls (Fig. S7A, B).  To test whether MHC-II expression patterns influence the tumor 
initiation potential of premalignant ISCs, we studied Lgr5-CreERt2;ApcL/L mice fed a 
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control or HFD diet prior to tamoxifen-induced inactivation of the tumor suppressor gene 
Apc. Whereas premalignant APCnull ISCs in control mice were mostly MHC-II+, APCnull 
MHC-II- ISCs in HFD mice expressed significantly less MHC-II both at RNA and protein 
levels (Fig. S7C-F). Interestingly, as we observed in the non-neoplastic intestine (Fig. 
S3G, H), MHC-II expression levels on APCnull ISCs did not affect their ability to form 
adenomatous organoids in vitro (Fig. 4A, B). This indicates that decreased MHC-II 
expression has no effect on the cell-intrinsic oncogenic potential of premalignant APCnull 
ISCs in organoid cultures in vitro.  
 
To test whether HFD-mediated downregulation of MHC-II in ISCs has pro-
tumorigenic effects in vivo under immune surveillance, we utilized a recently developed 
orthotopic, syngeneic colon transplantation assay in mice (Beyaz et al., 2016). We 
sorted APCnull MHC-II+ or APCnull MHC-II- Lgr5-GFPhi cells by flow cytometry and 
transplanted them into the colonic submucosa of syngeneic, immune-competent mice. 
In contrast to the in vitro organoid assay, APCnull MHC-II- Lgr5-GFPhi cells exhibited 
greater tumorigenicity when transplanted in vivo than their APCnull MHC-II+ counterparts 
(Fig. 4C, S7G-I). Notably, when transplanted to immunodeficient hosts that lack 
adaptive immune cells, both MHC-II+ and MHC-II- APCnull premalignant cells gave rise 
to equal numbers of tumors, highlighting the significance of MHC-II recognition by 
immune cells in controlling intestinal tumor initiation (Fig. 4D, S7J-L). Finally, to 
ascertain the role of epithelial MHC-II expression during intestinal tumorigenesis, we 
generated two genetic mouse models. First, using epithelial-specific inducible deletion 
model of MHC-II together with tumor suppressor Apc (vilCreERt2; ApcL/L; MHC-IIL/L), we 
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initated single tumors in the distal colon by administering 4-OHT with our endoscopy-
guided injection system. We found that mice with MHC-II KO allele (vil-Cre-ERt2 APCL/L, 
MHC-IIL/+) gave rise to larger tumors compared to mice with WT allele (vil-Cre-ERt2 
APCL/L, MHC-IIL/+) (Fig 4E, F). Second, we initiated tumors using Lgr5+ ISC-specific 
inducible deletion model of MHC-II together with one copy of the tumor suppressor Apc 
that leads to intestinal tumor formation due to loss of heterozygosity. While we did not 
detect significant difference in the numbers of T cells inflitrating the tumors at the time of 
analysis,  we found that specific loss of MHC-II in ISCs was associated with greater 
numbers of intestinal tumors compared to their MHC-II-proficient counterparts (Fig. 4G, 
S7M,O). These results illustrate that HFD-mediated reduction of MHC-II in premalignant 
ISCs enhances tumor initiation.  
 
Discussion 
ISCs self-renew and differentiate into cells that constitute the intestinal 
epithelium, which is continuously replenished (Clevers, 2013). Acquisition of oncogenic 
mutations in these rapidly cycling stem cells leads to tumors that are subject to 
clearance by T cells (Agudo et al., 2018; Barker et al., 2009; Schepers et al., 2012). It is 
also becoming increasingly evident that the crosstalk between tissue stem cells and 
immune cells influences differentiation, homeostasis and cancer risk (Ali et al., 2017; 
Biton et al., 2018b; Chakrabarti et al., 2018; Hoytema van Konijnenburg et al., 2017; 
Lindemans et al., 2015; Naik et al., 2018; Naik et al., 2017). Here, we find that a HFD 
dampens MHC-II expression in ISCs which can promote intestinal cancer by impacting 
immune surveillance through MHC II. While MHC-I antigen presentation pathway-
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mediated activation of cytotoxic CD8+ T cells is frequently studied in the context of anti-
tumor immune responses, MHC-II-mediated activation of CD4+ T cells is also pivotal for 
tumor immunity (Hung et al., 1998; Takeuchi and Saito, 2017; Tran et al., 2014; Wang, 
2001; Xie et al., 2010; Zhang et al., 2009). Indeed, recent studies have demonstrated 
that MHC-II-restricted CD4+ T cells are able to eradicate tumors both directly and 
indirectly through the licensing of dendritic cells and helping CD8+ T cell responses 
(Haabeth et al., 2016; Hirschhorn-Cymerman et al., 2012; Kreiter et al., 2015; Lu et al., 
2017; Spitzer et al., 2017; Tran et al., 2014). Consistent with previous studies 
demonstrating that tumors downregulate MHC-II expression to escape from immune 
surveillance (Park et al., 2017; Tarafdar et al., 2017), our data implicate dietary 
regulation of MHC-II expression in ISCs as playing a critical role in intestinal 
tumorigenesis. Whether diet-induced reduction in MHC-II expression in ISCs directly or 
indirectly affects anti-tumor CD4+ T cell responses warrants further investigation. 
 
We previously demonstrated that the activation of PPAR-d by the lipid 
constituents of a HFD is an ISC cell-intrinsic mechanism that enhances tumorigenicity in 
the intestine  (Beyaz et al., 2016). The findings presented here indicate that 
downregulation of MHC-II in ISCs in response to a HFD  provides an orthogonal 
mechanism contributing to intestinal cancer. Indeed, a recent large scale genome-wide 
variant scan for colorectal cancer identified variants associated with cancer risk in MHC-
II gene loci(Huyghe et al., 2018). Together, our results highlight how diet impacts 
multiple mechanisms that modify cancer risk in the intestine. Because a HFD influences 
cancer incidence in both mucosal and non-mucosal tissues (Beyaz et al., 2016; Chen et 
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al., 2018; Kroenke et al., 2013; Pascual et al., 2017; Schulz et al., 2014; Yang et al., 
2017; Yang et al., 2008), it will be important to explore whether MHC-II mediated 
immune surveillance of stem cells also takes place in other tissues and whether it is 
affected by dietary perturbations.   
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Materials and Methods 
 
 
Mice, High Fat Diet, and drug treatment 
Mice were housed in the Cold Spring Harbor Laboratory and Koch Institute for 
Integrative Cancer Research. The following strains were obtained from the Jackson 
Laboratory:  Lgr5-EGFP-IRES-CreERT2 (strain name: B6.129P2-Lgr5tm1(cre/ERT2)Cle/J, 
stock number 008875), Rosa26-lacZ (strain name: B6.129S4-Gt(ROSA)26Sortm1Sor/J, 
stock number 003474), db/db (strain name: B6.BKS(D)-Leprjb/J, stock number 000697), 
MhcL/L (strain name: B6.129X1-H2-Ab1tm1Koni/J, stock number 013181), IFNGR KO 
(C57BL/6N-Ifngr1tm1.2Rds/J, stock number 025545. Apcloxp exon 14 (ApcL/L) has been 
previously described(Colnot et al., 2004). Villin-CreERT2 was a gift from Sylvie Robine.  
Diet-induced obesity studies were performed by using a high fat diet consisting of 60 
kcal% fat (Research Diets D12492) beginning at the age of 8-12 weeks and extending 
for 9 to 14 months. Control mice were age- and sex-matched and were fed matched 
purified control diet (Research Diets, D12450J). GW501516 (Enzo) was reconstituted in 
DMSO at 4.5mgml−1 and diluted 1:10 in a solution of 5% PEG400 (Hampton 
Research), 5% Tween80 (Sigma), 90% H2O (injection buffer) for a daily intraperitoneal 
injection of 4mg kg−1. Apc exon 14 was excised by tamoxifen suspended in sunflower 
seed oil (Spectrum S1929) at a concentration of 10 mg ml-1 and 250 μl per 25g of body 
weight, and administered by intraperitoneal injection twice over 4 days before 
harvesting tissue. BrdU (Sigma) was prepared at 10 mg ml-1 in PBS, passed through 
0.22μm filter and injected at 100mg kg-1. CYT387 (SelleckChem) was reconstituted in 
DMSO at 10mg ml-1 and diluted 1:100 in injection buffer for a daily gavage of 25mg kg−1 
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for 7 days. CL429 (InvivoGen) was reconstituted in DMSO at 5mg ml-1 and diluted 1:20 
in a solution of injection buffer for a daily gavage of 2mg kg-1 for 7 days. For broad-
spectrum antibiotic treatment, mice received a mixture of vacomycin (0.5g/l), ampicillin 
(1g/l), metronidazole (1g/l) and neomycin (1g/l) in the drinking water. 
 
Immunohistochemistry (IHC) and immunofluorescence (IF) 
As previously described(Yilmaz et al., 2012), tissues were fixed in 10% formalin, 
paraffin embedded and sectioned. Antigen retrieval was performed with Borg Decloaker 
RTU solution (Biocare Medical) in a pressurized Decloaking Chamber (Biocare Medical) 
for 3minutes. Antibodies used: rat anti-BrdU (1:2000, Abcam 6326), mouse 
monoclonal β-catenin (1:100, BD Biosciences 610154), rabbit monoclonal OLFM4 
(1:10,000, gift from CST, clone PP7), Biotin-conjugated secondary donkey anti-rabbit or 
anti-rat antibodies were used from Jackson ImmunoResearch. The Vectastain Elite 
ABC immunoperoxidase detection kit (Vector Labs) followed by Dako Liquid DAB+ 
Substrate (Dako) was used for visualization. All antibody incubations involving tissue or 
sorted cells were performed with Common Antibody Diluent (Cell Signaling).  
 
In situ hybridization 
Single-molecule in situ hybridization was performed to detect MHC-II (H2-Ab1, 
#414731) using Advanced Cell Diagnostics RNAscope 2.5 HD Detection Kit following 
manufacturer’s instructions. 
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Flow cytometry and isolation of ISCs and Paneth cells 
As previously reported and briefly summarized here, small intestines and colons were 
removed, washed with cold PBS-/-, opened laterally and cut into 3-5mm fragments. 
Pieces were washed multiple times with cold PBS-/- until clean, washed 2-3 with PBS-/-
/EDTA (10mM), and incubated on ice for 90-120 minutes while mixing at 30-minute 
intervals. Crypts were then mechanically separated from the connective tissue by 
shaking, and filtered through a 70-µm mesh into a 50-ml conical tube to remove villus 
material (for small intestine) and tissue fragments. Crypts were removed from this step 
for crypt culture experiments and embedded in MatrigelTM with crypt culture media. For 
ISC isolation, the crypt suspensions were dissociated to individual cells with TrypLE 
Express (Invitrogen). Cell labeling consisted of an antibody cocktail comprising IA-PE 
(eBioscience, 30-F11, 1:500), EPCAM APC (eBioscience, G8.8, 1:100), CD11b-APC-
Cy7 (eBioscience, 1:500), and CD45 Pacific Blue (eBioscience, 1:500). Dead cells were 
excluded from the analysis with the viability dye 7-AAD (Life Technologies). ISCs were 
isolated as Lgr5-EGFPhiEpcam+ CD45−7-AAD− with a BD FACS Aria II SORP cell sorter 
into supplemented crypt culture medium for culture.  
Culture media for crypts and isolated cells 
Isolated crypts were counted and embedded in MatrigelTM (Corning 356231 growth 
factor reduced) at 5–10 crypts per μl and cultured in a modified form of medium as 
described previously(Sato et al., 2009b). Unless otherwise noted, Advanced DMEM 
(Gibco) was supplemented by EGF 40ngml−1 (R&D), Noggin 
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200ngml−1 (Peprotech), R-spondin 500ngml−1 (R&D or Sino Biological), N-acetyl-
L-cysteine 1μM (Sigma-Aldrich), N2 1X (Life Technologies), B27 1X (Life 
Technologies), Chiron 10 μM (Stemgent), Y-27632 dihydrochloride monohydrate 20ng 
ml−1 (Sigma-Aldrich). 25μL drops of MatrigelTM with crypts were plated onto a flat 
bottom 48-well plate (Corning 3548) and allowed to solidify for 20minutes in a 37°C 
incubator. Three hundred microliters of crypt culture medium was then overlaid onto the 
MatrigelTM, changed every three days, and maintained at 37°C in fully humidified 
chambers containing 5% CO2. Clonogenicity (colony-forming efficiency) was calculated 
by plating 50–300 crypts per well and assessing organoid formation 3–7days or as 
specified after initiation of cultures.   
Isolated ISCs or progenitor cells were centrifuged for 5minutes at 250g, re-suspended 
in the appropriate volume of crypt culture medium (500–1,000cellsμl−1), then seeded 
onto 25-30 μl MatrigelTM (Corning 356231 growth factor reduced) containing 1μM 
Jagged (Ana-Spec) in a flat bottom 48-well plate (Corning 3548). Alternatively, ISCs and 
Paneth cells were mixed after sorting in a 1:1 ratio, centrifuged, and then seeded onto 
MatrigelTM. The MatrigelTM and cells were allowed to solidify before adding 300 μl of 
crypt culture medium. The crypt media was changed every second or third day. 
Organoid bodies were quantified on days 3, 7 and 10 of culture, unless otherwise 
specified. In secondary experiments, individual primary organoids were mechanically 
dissociated and replated, or organoids were dissociated for 10 minutes in TrypLE 
Express at 32ºC, resuspended with SMEM (Life Technologies), centrifuged and 
resuspended in cold SMEM with viability dye 7-AAD. Live cells were sorted and seeded 
onto MatrigelTM as previously described. 
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Bulk RNA-Seq  
RNA Isolation. For RNA-seq, total RNA was extracted from 200K sorted Lgr5-GFPhi 
ISCs or Lgr5-GFPlow progenitors by pooling two to five 71-week old male mice per HFD 
and HFD-control using Tri Reagent (Life Technologies) according to the manufacturer's 
instructions, except for a overnight isopropanol precipitation at –20°C. From the total 
RNA, poly(A)+ RNA was selected using Oligo(dT)25-Dynabeads (Life technologies) 
according to the manufacturer’s protocol. 
RNA-Seq Library Preparation. Strand-specific RNA-seq libraries were prepared using 
the dUTP-based, Illumina-compatible NEXTflex Directional RNA-Seq Kit (Bioo 
Scientific) according to the manufacturer’s directions. All libraries were sequenced with 
an Illumina HiSeq 2000 sequencer. 
Processing of RNA-seq reads and measuring expression level. Raw stranded reads (40 
nt) were trimmed to remove adapter and bases with quality scores below 20, and reads 
shorter than 35 nt were excluded. High-quality reads were mapped to the mouse 
genome (mm10) with TopHat version 1.4.1 (Trapnell et al., 2009), using known splice 
junctions from Ensembl Release 70 and allowing at most 2 mismatches. Genes were 
quantified with htseq-count (with the “intersect strict” mode) using Ensembl Release 70 
gene models. Gene counts were normalized across all samples using 
estimateSizeFactors() from the DESeq R/Bioconductor package(Anders and Huber, 2010). 
Differential expression analysis was also performed between two samples of interest 
with DESeq.  
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qRT-PCR 
Cells were sorted into Tri Reagent (Life Technologies) and total RNA was isolated 
according to the manufacturer's instructions with following modification: the aqueous 
phase containing total RNA was purified using RNeasy plus kit (Qiagen). RNA was 
converted to cDNA with cDNA synthesis kit (Bio-Rad). qRT-PCR was performed with 
SYBR green master mix (Bio-Rad) on Bio-Rad iCycler RT-PCR detection system. For 
low cell numbers (<1000), qRT-PCR was performed after sequence specific pre-
amplification as described in single-cell gene expression analysis. Primers used are 
listed on Supplementary Table 1. 
 
Single cell RNA-Seq 
Cell sorting 
FACS (Astrios) was used to sort one single cell into each well of a 96-well PCR plate 
containing 5µl of TCL buffer with 1% 2-mercaptoethanol. The cells were stained for 
7AAD- (Life Technologies), CD45- (eBioscience), CD31- (eBioscience), Ter119- 
(eBioscience), EpCAM+ (eBioscience). To enrich for specific IEC populations, cells were 
isolated from control or HFD Lgr5-GFP mice, stained with the antibodies mentioned 
above and gated for GFP-high (stem cells) and GFP-low (TAs). A population control of 
200 cells was sorted into one well and a no-cell control was sorted into another well. 
After sorting, the plate was sealed tightly with a Microseal F and centrifuged at 800g for 
1 min. The plate was immediately frozen on dry ice and kept at -80ºC until ready for the 
lysate cleanup.  
Plate-based scRNA-seq 
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Libraries were prepared using a modified SMART-Seq2 protocol as previously reported 
(Picelli et al., 2014). Briefly, RNA lysate cleanup was performed using RNAClean XP 
beads (Agencourt), followed by reverse transcription with Maxima Reverse 
Transcriptase (Life Technologies) and whole transcription amplification (WTA) with 
KAPA HotStart HIFI 2× ReadyMix (Kapa Biosystems) for 21 cycles. WTA products were 
purified with Ampure XP beads (Beckman Coulter), quantified with Qubit dsDNA HS 
Assay Kit (ThermoFisher), and assessed with a high sensitivity DNA chip (Agilent). 
RNA-seq libraries were constructed from purified WTA products using Nextera XT DNA 
Library Preparation Kit (Illumina). On each plate, the population and no-cell controls 
were processed using the same method as the single cells. The libraries were 
sequenced on an Illumina NextSeq 500.  
Computational analysis of scRNA-seq 
 
We profiled Lgr5-high ISCs sorted from control (n=192 cells) and HFD (n=192 cells) 
using a full length scRNA-seq method (Picelli et al., 2014). Each condition included two 
replicate 96-well plates from 2 different mice. Expression levels of gene loci were 
quantified using RNA-seq by Expectation Maximization (RSEM) (Li and Dewey, 2011). 
Raw reads were mapped to a mouse transcriptome index (mm10 UCSC build) using 
Bowtie 2 (Langmead and Salzberg, 2012), as required by RSEM in its default mode. On 
average, 90% of the reads mapped to the genome in every sample. and 55% of the 
reads mapped to the transcriptome. RSEM yielded an expression matrix (genes x 
samples) of inferred gene counts, which was converted to TPM (transcripts per million) 
values and then log-transformed after the addition of 1 to avoid zeros. After filtering cells 
with low QC metrics (< 400,000 mapped reads, transcriptomic mapping rate < 35% and 
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< 1500 genes detected),  we selected 171 control cells and 144 HFD cells for further 
analysis. 
 
We identified 379 highly variable genes using Seurat’s MeanVarPlot function. H2-Ab1, a 
key component of MHC-II complex, was among the top 5 differentially expressed genes 
with > 3-fold higher expression in control compared to HFD ISCs as assessed using 
MAST test.(Finak et al., 2015) A Gene Ontology analysis of these genes against a 
background of genes matched in average expression levels showed an enrichment of 
terms consistent with intestinal biology such as arachidonic acid metabolic process 
(GO:0019369), intestinal absorption (GO:0050892), as well as immune response, such 
as “antigen processing and presentation of exogenous peptide antigen” (GO:0002478) 
and “defense response to Gram-negative (GO:0050829), and Gram-positive 
(GO:0050830) bacterium”. We performed principal component analysis (PCA) on the 
data based on the variable genes, and embedded 10 statistically significant PCs 
identified using a permutation test (Shekhar et al., 2016) on a 2D map using t-
distributed stochastic neighbor embedding (tSNE). 
 
DQ-Ovalbumin Assay 
Lgr5-GFPhi intestinal stem cells were plated in Matrigel and crypt media for one day. 
The following day, the crypt media was replaced with crypt media containing 20 µg/mL 
DQ-ovalbumin (Invitrogen) and cells were incubated at 4C and 37C for 24 hours. Cells 
were harvested by washing three times in PBS, removing the Matrigel using Cell 
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Recovery Solution (Corning) and filtered through a 40 µm mesh. Mean fluorescent 
intensity was analyzed using CellSimple (Cell Signaling).  
Orthotopic transplantation 
ApcL/L; Lgr5-EGFP-IRES-CreERT2 mice were injected with two doses of tamoxifen I.P. 
Four days later, Apc-null Lgr5-GFPhi ISCs and Lgr5-GFPlow progenitors were sorted by 
flow cytometry, as described above. For primary cell transplantations, 10,000 Apc-null 
Lgr5-GFPhi , MHChi and MHClow ISCs were resuspended into 90% crypt culture media 
(as described) and 10% MatrigelTM, and then transplanted into the colonic lamina 
propria of C57BL/6 recipient mice as previously described (Beyaz et al., 2016; Roper et 
al., 2017).  Mice then underwent colonoscopy eight weeks later to assess tumor 
formation. Colonoscopy videos and images were saved for offline analysis. Following 
sacrifice, the distal colons were excised and fixed in 10% formalin, then examined by 
hematoxylin and eosin section to identify adenomas. Histology images were reviewed 
by gastrointestinal pathologists who were blinded to treatment groups.  
Taxonomic Microbiota Analysis. 
Frozen fecal samples were processed for DNA isolation using the Qiagen PowerSoil kit 
according to the manufacturer’s instructions. 1 ng of purified fecal DNA was used for 
PCR amplification. Amplicons spanning the variable region 1/2 (V1/2) of the 16S rRNA 
gene were generated by using the following barcoded primers: Fwd 5’-
XXXXXXXXAGAGTTTGATCCTGGCTCAG-3’, Rev 5’-TGCTGCCTCCCGTAGGAGT-3’, 
where X represents a barcode base. The reactions were subsequently pooled and 
cleaned, and the PCR products were then sequenced on an Illumina MiSeq with 500 bp 
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paired-end reads. The reads were then processed using the QIIME (Quantitative 
Insights Into Microbial Ecology, http://www.qiime.org) analysis pipeline. Rarefaction was 
used to exclude samples with insufficient count of reads per sample. Sequences 
sharing 97% nucleotide sequence identity in the 16S region were binned into 
operational taxonomic units (97% ID OTUs). For beta-diversity, unweighted UniFrac 
measurements were plotted according to the two principal coordinates based on 
>10,000 reads per sample. 
 
Figure Legends 
Figure 1 | High Fat Diet reduces MHC-II expression on Lgr5-GFPhi intestinal 
stem cells (ISCs). 
A. A heat map of downregulated genes assessed by bulk RNA-seq in Lgr5-GFPhi 
intestinal stem cells (Lgr5+ ISCs) isolated from long-term high fat diet (HFD)-fed mice 
compared to control mice (n=2).  
B. Violin plots demonstrating MHC-II expression in single ISCs isolated from 
control (n=171 cells, 2 independent experiments) or HFD mice by single cell RNA-seq 
(scRNA-seq) (n=144 cells, 2 independent experiments). 
C. Control (blue) and HFD (red) Lgr5+ ISCs ranked according to their expression 
of MHC II pathway genes (y-axis). Dashed lines correspond to y-intercepets of -0.2 and 
0.75, which are the 25th and 75th percentile of scores in HFD cells, used to define MHC2 
low (score < -0.2) and MHC2 high (score > 0.75) HFD cells. In contrast, these values 
correspond to 1st and 35th percentile of scores in control cells. 
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D. Heatmap showing differentially expressed (DE) genes (rows) between MHC2 
low and MHC2 high HFD ISCs as defined in panel C. 
E. Single-molecule in situ hybridization of MHC-II (H2-Ab1) in control and HFD 
mice (n=5).  
F, G. Mean fluorescence intensity (MFI) of MHC-II in Epcam+ cells from crypts of 
control and HFD mice (F, n=10 mice). Representative flow cytometry histogram plots of 
MHC-II expression in Epcam+ cells (G).   
 
H. Relative expression of MHC-II (H2-Ab1) in Epcam+ cells isolated from crypts 
of control and HFD mice (n=10 mice).   
I, J. Mean fluorescence intensity (MFI) of MHC-II in Lgr5+ ISCs from crypts of 
control and HFD mice (I, n=10 mice). Representative flow cytometry histogram plots of 
MHC-II expression in Epcam+ cells (J).   
K. Relative expression of MHC-II (H2-Ab1) in Lgr5+ ISCs isolated from crypts of 
control and HFD mice (n=10 mice).   
L, M. Frequency of MHC-II+ and MHC-II- ISCs in control and HFD mice by flow 
cytometry (L, n=4, mean±s.d). Representative flow cytometry plots of MHC-II in 
control and HFD ISCs (M).  
Unless otherwise indicated, data are mean±s.e.m. from n independent experiments; 
*P<0.05, **P<0.01, ***P<0.001 (Student’s t-tests). Scale bars, 50μm (E) and 
20μm (E, inset). 
 
Figure 2 | Intestinal microbiome regulates MHC-II expression in ISCs  
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A. In situ hybridization for H2-Ab1 in control, HFD, and antibiotic-treated mice in 
proximal small intestine (n=5).  
B. Relative expression of MHC-II in Lgr5+ ISCs from control, HFD, and antibiotic-
treated mice (n=5, mean±s.d).  
C. Single-molecule in situ hybridization of MHC-II (H2-Ab1) in specific pathogen-
free (SPF) and germ-free mice (n=5 mice). 
D. Relative expression of MHC-II (H2-Ab1) in Lgr5+ ISCs from SPF and germ-
free mice (n=5). 
E, F. Mean fluorescence intensity (MFI) of MHC-II in Lgr5+ ISCs from SPF and 
germ-free mice (E, n=5). Representative flow cytometry histogram plots of MHC-II 
expression in Lgr5+ ISCs (F). 
G. Volcano plot demonstrating significantly enriched and depleted microbial 
species in HFD versus control mice (n=5). 
H. Relative abundance of Helicobacter sp. in mice housed in clean room and 
dirty room (n=5).  
I. Volcano plot demonstrating significantly enriched and depleted microbial 
species in mice housed in dirty room versus clean room (n=6). 
J. Relative expression of MHC-II (H2-Ab1) in Epcam+ cells isolated from crypts 
of mice housed in clean room or dirty room (n=7). 
K. Relative abundance of Helicobacter sp. in mice housed either in clean room 
(n=10), dirty room (n=3), or after co-housing clean mice (n=10) with dirty mice (n=4) in 
dirty room. 
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L. Relative expression of MHC-II (H2-Ab1) in Epcam+ cells isolated from crypts 
of mice housed either in clean room, dirty room, or after co-housing clean mice with 
dirty mice in dirty room (n=5, ANOVA). 
M, N. Mean fluorescence intensity (MFI) of MHC-II in Epcam+ cells isolated from 
crypts of mice housed either in clean room, dirty room, or after co-housing clean mice 
with dirty mice in dirty room (M, n=5, ANOVA). Representative flow cytometry histogram 
plots of MHC-II expression in Lgr5+ ISCs (N). 
Unless otherwise indicated, data are mean±s.d. from n independent experiments; 
*P<0.05, **P<0.01, ***P<0.001 (Student’s t-tests).  
 
Figure 3 | PRR and IFN γ signaling regulate MHC-II expression in ISCs. 
A. Relative expression of pattern recognition receptors (PRR) in control and HFD 
ISCs (n=3).  
B. Mean fluorescence intensity (MFI) of MHC-II in ISCs from vehicle- and 
TLR2/NOD2 agonist CL429- treated control and HFD mice (n=6 mice).  
C. A heat map of expression levels of IFN γ-induced genes between HFD and 
control ISCs by bulk RNA-seq (n=2).  
D. Violin plots demonstrating the expression levels of IFN γ-induced genes in 
control and HFD ISCs by scRNA-seq. 
E. IFN γ levels in the intestines of control and HFD mice as measured by ELISA 
(n=10). 
F. In situ hybridization for H2-Ab1 in vehicle- and CYT387-treated mice in small 
intestine (n=3). 
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G. Relative expression of MHC-II (H2-Ab1) in Lgr5+ ISCs from vehicle- and 
Jak/Stat inhibitor CYT387-treated mice (n=7). 
H, I. Mean fluorescence intensity (MFI) of MHC-II in Lgr5+ ISCs from vehicle- 
and CYT387-treated mice (H, n=5). Representative flow cytometry histogram plots of 
MHC-II expression in Lgr5+ ISCs (I).  
J. Relative expression of MHC-II (H2-Ab1) in intestinal organoids-treated with or 
without CYT387 and/or IFN γ (n=5). 
K. Relative expression of MHC-II (H2-Ab1) in Epcam+ cells isolated from crypts 
of control or IFNGR KO (n=5). 
Unless otherwise indicated, data are mean±s.e.m from n independent experiments; 
*P<0.05, **P<0.01, ***P<0.001 (Student’s t-tests).  
 
Figure 4 | Loss of MHC-II in premalignant ISCs increases tumor initiation.   
A, B. Organoid-initiating capacity of control and HFD MHC-II+ and MHC-II- Apc-
null ISCs at day 5 (control MHC-II+, n=3, control MHC-II-, n=3, HFD MHC-II+, n=4, HFD 
MHC-II-, n=4). Representative images of HFD MHC-II+ and MHC-II- Apc-null organoids 
at day 5 (B).  
C. Tumor initiation rate of orthotopically transplanted MHC-II+ and MHC-II- Apc-
null ISCs from HFD mice into immunocompetent syngeneic hosts (n=8). 
D. Tumor initiation rate of orthotopically transplanted MHC-II+ and MHC-II- Apc-
null ISCs from HFD mice into immunodeficient (Rag2 KO) hosts (n=8). 
E, F. Tumor size index in distal colon of mice that received tamoxifen through 
endoscopy guided tamoxifen injection to induce tumor formation upon loss of APC (E, 
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n=6, MHC-II WT APC KO: villin-Cre-ERt2 APC L/L, MHC-II L/+, MHC-II iKO APC KO: 
villin-Cre-ERt2 APC L/L, MHC-II L/L). Representative optical colonoscopy images of 
tumors (F). 
G. Number of tumors per small intestine in Lgr5-CreERt2 APC+/- MHC-II+/- (n=9, 
MHC-II WT APC-het) and Lgr5-GFP+ APC+/- MHC-/- (n=9, MHC-II iKO APC KO) mice 5 
months post tamoxifen injection.   
Unless otherwise indicated, data are mean±s.e.m from n independent 
experiments; *P<0.05, **P<0.01, ***P<0.001 (Student’s t-tests). 
 
 Supplementary Figure 1 | Characterization of the MHC-II+ and MHC-II- ISCs.  
A. Relative expression of immunomodulatory genes in control and HFD Lgr5-
GFPhi ISCs (n=5). 
B. t-Distributed stochastic neighbour embedding (tSNE) analysis of single ISCs 
isolated from control (n=171 cells, 2 independent experiments) or HFD mice (n=144 
cells, 2 independent experiments). 
C. tSNE analysis of single cells using MHC-II pathway signature genes 
D. Relative expression of MHC-II in control and HFD MHC-II+ and MHC-II- ISCs 
(n=5).  
E. Relative expression of signature PPAR-d target (Hmgcs2), stem cell marker 
(Lgr5), PPAR-d-dependent B-catenin target (Jag1) and IFNGR genes in control and 
HFD MHC-II+ and MHC-II- ISCs (n=5).  
F. Organoid-initiating capacity of MHC-II+ and MHC-II- Lgr5-GFPhi ISCs from 
HFD mice (n=5). 
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G. Mean fluorescence intensity (MFI) of ISCs pulsed with either vehicle or DQ-
Ovalbumin for 8 hours at 4C and 37C (n=5, 3 technical replicates per experiment). 
H. Weight of mice used for diet-induced obesity (left: Control and HFD, n=15) 
and leptin receptor deficiency models of obesity (right, Control and db/db, n=7) in the 
study. 
I, J. Frequency of MHC-II+ and MHC-II- ISCs in vehicle- and PPAR-delta agonist 
GW501516-treated mice by flow cytometry (I, n=3). Representative flow cytometry plots 
of MHC-II in vehicle- and PPAR-delta agonist GW501516-treated ISCs (J).  
K, L. Frequency of MHC-II+ and MHC-II- ISCs in lean db/+ and obese db/db 
mice (K, n=3). Representative flow cytometry plots of MHC-II+ and MHC-II- ISCs (I, 
n=3).  
Unless otherwise indicated, data are mean±s.d. from n independent experiments; 
*P<0.05, **P<0.01, ***P<0.001 (Student’s t-tests).  
 
Supplementary Figure 2 | Intestine-specific deletion of MHC-II does not 
significantly alter intestinal physiology.  
A-E, Intestinal weight (a, n=5), length (b, n=5), crypt (c, n=5), and villi length (d, 
n=5) of MHC-II wild type (WT) and MHC-IIL/L; Villin-CreERT2 (vil-iKO) mice one month 
after tamoxifen injection. Representative H&Es of WT and vil-iKO small intestine (E).   
F, G, In situ hybridization for H2-Ab1 in the intestine (F) and representative 
images of intestinal crypts (G) in WT and vil-iKO mice (n=3).  
H. Frequencies of MHC-II+ and MHC-II- Lgr5-GFPhi ISCs in WT and Lgr5-GFP 
MHC-II-deleted (Lgr5-iKO) by flow cytometry (n=5). 
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I. Lineage tracing of LacZ+ cells in the intestinal crypt after deletion of MHC-II in 
ISCs (left). Representative images of LacZ immunostain in WT and Lgr5-iKO small 
intestine (right). 
Unless otherwise indicated, data are mean±s.d. from n independent 
experiments; *P<0.05, **P<0.01, ***P<0.001 (Student’s t-tests). Scale bars, 
100μm (E), 50μm (F, I, K) and 20μm (G, I, (insets)). 
 
Supplementary Figure 3 | Intestine-specific deletion of MHC-II does not 
alter the organoid forming capacity of ISCs.   
A, B. Number of bromodeoxyuridine (BrdU)+ crypt base columnar cells after a 4-
hour pulse in MHC-IIL/L; Villin-CreERT2 (vil-iKO) mice after tamoxifen administration 
(WT: n=3, vil-iKO: n=4). Representative images of BrdU immunostain in proximal small 
intestinal crypts (B).  
C-E Organoid-initiating capacity of WT and vil-iKO crypts (C, n=5). Number of 
secondary organoids per dissociated crypt-derived primary organoid (D, n=5). 
Representative images of day-5 WT and vil-iKO primary organoids (E).  
F. Relative expression of MHC-II in dissociated WT and vil-iKO primary 
organoids at day 5 (n=5). 
G, H. Organoid-initiating capacity of ISCs from WT and MHC-IIL/L; Lgr5-EGFP-
IRES-CreERT2 (Lgr5-iKO) mice with and without Paneth cells (P) from WT mice (n=5). 
Representative images of organoids derived from WT and Lgr5-iKO ISCs co-cultured 
with WT Paneth cells five days after seeding (H).  
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Unless otherwise indicated, data are mean±s.d. from n independent experiments; 
*P<0.05, **P<0.01, ***P<0.001 (Student’s t-tests). Scale bars, 100μm (E, H) 
and 20μm (B).  
 
Supplementary Figure 4 | Microbial regulation of MHC-II expression in ISCs. 
A. Chao1 index of microbial diversity in Control, HFD, and mice treated with 
antibiotics for 3 months (n=5).  
B. Principle component analysis of microbial diversity in Control, HFD, and 
antibiotic-treated mice (n=5). 
C, D. Frequencies of MHC-II+ and MHC-II- ISCs in specific-pathogen free (SPF) 
and germ-free mice by flow cytometry (n=3). Representative flow cytometry plots of 
MHC-II in SPF and germ-free ISCs (D).  
E. Principle component analysis of microbial diversity in mice housed in clean 
room or dirty room (n=6). 
F. Relative abundance of Odoribacter sp. in mice housed in clean room or dirty 
room (n=6). 
G. Principle component analysis of microbial diversity at baseline level before co-
housing experiment (left) and 10 days after co-housing clean mice with dirty mice in the 
dirty room. 
 
Unless otherwise indicated, data are mean±s.d. from n independent experiments; 
*P<0.05, **P<0.01, ***P<0.001 (Student’s t-tests).  
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Supplementary Figure 5 | Regulation of MHC-II expression in ISCs by PRR 
and Jak/Stat signaling.  
A, B. In situ hybridization for H2-Ab1 in control and HFD mice treated with 
vehicle- and CL429-treated mice in proximal small intestine (A, n=3). Representative 
histogram plots of MHC-II in ISCs in control and HFD mice treated with vehicle and 
CL429 (B, n=3).  
C. In situ hybridization for H2-Ab1 in WT and Myd88 KO mice (n=4). 
D. Relative expression of Myd88 and MHC-II genes (H2-Aa and H2-Ab1) in the 
intestine from WT and Myd88 KO mice (n=5). 
E. Relative expression of MHC-II (H2-Ab1) in MHC-II+ and MHC-II- ISCs isolated 
from HFD mice with or without IFNg stimulation (n=4).   
F. Violin plots demonstrating the levels of IFNg-induced genes excluding MHC-II 
pathway genes in control and HFD ISCs by scRNA-seq. 
 
G. Violin plots demonstrating the levels of STAT3 in control and HFD ISCs by 
scRNA-seq. 
H, I. Frequencies of MHC-II+ and MHC-II- ISCs in vehicle- and Jak/Stat inhibitor 
CYT387-treated mice (n=3). Representative flow cytometry plots of MHC-II in vehicle- 
and CYT387-treated ISCs (I).  
Unless otherwise indicated, data are mean±s.d. from n independent experiments; 
*P<0.05, **P<0.01, ***P<0.001 (Student’s t-tests). Scale bars, 50μm (A, C) 
and 20μm (insets, A). 
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Supplementary Figure 6 | The effect of HFD on intestinal immune cells 
A. Frequency of CD45+ cells in intestinal crypts isolated from control or HFD 
mice (n=7). 
B. Frequency of CD3+ T cells, CD8+ T cells and CD4+ T cells among CD45+ 
cells in intestinal crypts isolated from control or HFD mice (n=5).  
C-H. Numbers of CD8+ cells (C, crypt; D, villus) and CD4+ cells (E, crypt; F, 
villus) in the intestines of control or HFD mice. Representative images of CD4 and CD8 
immunostaining in control or HFD intestines (G, H).  
 
Supplementary Figure 7 | The effect of ISC MHC-II expression on tumor 
formation.  
A, B. Fraction of H2-Ab1+ tumor areas per total tumor area by single-molecule in 
situ hybridization in control and HFD Lgr5+ Apc-null mice 14 days post tamoxifen 
injection (Control, n=6; HFD, n=5). Representative images of H2-Ab1 in situ 
hybridization in control and HFD tumors from Lgr5+ Apc-null mice (B).  
C. Relative expression of MHC-II (H2-Ab1) in Lgr5+ Apc-null pre-malignant ISCs 
isolated from control or HFD mice 3 days post tamoxifen injection (n=5).  
D. Mean fluorescence intensity (MFI) of MHC-II in Lgr5+ Apc-null pre-malignant 
ISCs isolated from control or HFD mice 3 days post tamoxifen injection (n=6). 
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E, F. Frequency of MHC-II+ and MHC-II- Lgr5-GFPhi Apc-null ISCs in control and 
HFD mice by flow cytometry (E, n=5). Representative flow cytometry plots of MHC-II in 
HFD Apc-null ISCs (F). 
G-I. Characterization of orthotopically transplanted MHC-II+ and MHC-II- Apc-null 
ISCs-derived tumors three months after transplantation into immunocompetent 
syngeneic hosts. Optical colonoscopy images (G), Hematoxylin and eosin (H) and beta-
catenin immunostain (I) of tumors.  
J-L. Characterization of orthotopically transplanted MHC-II+ and MHC-II- Apc-
null ISCs-derived tumors three months after transplantation into immunodeficient Rag2-
KO hosts. Optical colonoscopy images (J), H&E (K) and beta-catenin immunostain (L) 
of tumors.  
M-O. Tumors in Lgr5-Cre+ APC+/- MHC+/- (MHC-II WT) and Lgr5-Cre+ APC+/- 
MHC-/- (MHC-II iKO) mice. Representative images of tumors from Lgr5-Cre+ APC+/- 
MHC+/- (M, left) and Lgr5-Cre+ APC+/- MHC-/- (M, right) mice. Representative H&E (N) 
and beta-catenin immunostain (O) images from tumors in Lgr5-GFP+ APC+/- MHC+/- and 
Lgr5-GFP+ APC+/- MHC-/- mice.  
P-R. Numbers of CD3+ T cells per tumor area (P). Representative H&E (N) and 
CD3 immunostain (O) images from tumors. 
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